EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
Despite The Controversy, Blockbuster Status Is Predicted
Executive Summary
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.